Pfizer's Q4 2024 Lobby Spend -- Compared To Prior Three Years -- Is Down Quite A Bit...

While Amgen has also been a large spender in the last four years, overall -- it has been Pfizer (partly due to larger market cap) that led the pack for the last decade among pharma majors.

This year though, Pfizer decided to mostly sit out the election year, making Merck the runaway leader (for the full year). At least for 2024. It seems highly likely Pfizer will spend heavily in 2025 to blunt the Kennedy Jr. effect. All of Tangerine 2.0's talk about being a populist, and seeking lower drug prices, for consumers. . . is just that: idle talk. He will do as PhRMA tells him -- but Kennedy is a bit of a wild card, at least as to vaccines. Should be entertaining. Here's Pfizer's Q4 2024:

▲. . .Inflation Reduction Act (IRA); HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act; Medicare Price Setting; Drug Shortages; Global Access to Medicines; Trade-Related Aspects of Intellectual Property Rights (IPR); March-in Framework Guidance and Policies; S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023; S 142 - Preserve Access to Affordable Generics and Biosimilars Act; HR 6986 - To address patent thickets; S 150 - Affordable Prescriptions for Patients Act of 2023; S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act; Antimicrobial Resistance; PBM Transparency and Reform; S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act; S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act; S 2973 - Modernizing and Ensuring PMB Accountability Act; 340B Reform; HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act. . . .

▲ S 723/HR 1458 - Access to Prescription Digital Therapeutics Act; HR 8816 - American Medical Innovation and Investment Act of 2024. . . .

▲ Comprehensive Corporate Tax Reform; Tax Cuts and Jobs Act (TCJA); VICP Reform and Excise Tax; Vaccine Injury Compensation Fund; VICP Transition; Comprehensive Federal Tax Reform. . . .

▲ International Supply Chain; HR 4307/S 2115 - Medical Supply Chain Resiliency Act. . . .

Now you know -- and I may ignore Lilly this time around, as it only spent $190,000 in the whole fourth quarter. It was always spending less than the peers -- but it just. . . disappeared, in Q4. I suspect the plan is a new push on insulins, and on the weight loss meds. . . here in the new year 2025. We shall see, but maybe they think they don't need the spend with Tangerine 2.0 in office. If that is the view in Indy. . . it is an. . . unwise one. Onward.

नमस्ते